anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
FIELD: food industry. ^ SUBSTANCE: invention relates to medicine and food industry and may be used to produce biologically active supplements (BAS) with the main reactant produced from cysts of Artemia salina maxillopod. Technical result is achieved by the fact that supplement additionally contains nutmeg fruits ground down to finely dispersed condition and pine nut shell ground down to finely dispersed condition at the following ratio of components, wt %: nutmeg powder - 4-6; powder of pine nut shell - 15-35; powder of dry cysts of Artemia salina - 60-80. Powder of dry cysts of Artemia salina may be ground by available methods and is fractionated so that particle size does not exceed 30 mcm. Soluble substances present in powder of specified dispersion quite easily dissolve in user&#39;s gastric juice, insoluble particles produce beneficial effect at intestine walls, cleaning them. Powder of pine nut shell and nutmeg may also be ground and fractionated so that particle size does not exceed 30 mcm. Soluble substances present in powder of specified dispersion quite easily dissolve in user&#39;s gastric juice, insoluble particles produce beneficial effect at intestine walls, cleaning them. Invention may be used to produce food supplements as prophylactics agent and as an auxiliary substance in treatment of avitaminosis, obesity, etc. ^ EFFECT: improved biological activity and efficiency, as well as wider range of general health-improving food supplements. ^ 4 cl
Devices, systems, and methods are provided for adherence monitoring and patient interaction. In general, the devices, systems, and methods can facilitate a patient&#39;s adherence to a medication schedule and can facilitate monitoring and tracking of the patient&#39;s adherence to the medication schedule. In one embodiment, a medical accessory such as a cap is provided that can be configured to attach to existing medication dispensers, such as asthma inhalers, or to be integrated into a custom-made medication dispenser. The accessory can be configured to provide a notification to the patient when medication is due. The accessory can be configured to detect usage of the dispenser. The accessory can be configured to provide data regarding dispensing of the medication to an external device. The data can be analyzed and provided for visualization on a user interface.
PROBLEM TO BE SOLVED: To enhance a commercial value and to obtain the mental satisfaction of an owner by permitting tail parts connected to body parts to be freely rockable in right and left directions in accordance with the action of an accessory by means of a pin and permitting the pupils of eye parts to be freely acting. SOLUTION: Body part mainbodies 6 are made by casting and are previously casting- formed by bisecting with a frame body 7 and a cavity part 8 is formed respectively inside the body part mainbodies 6. The tail parts 9&#39; independently formed against the body part mainbodies 6 and a pin 14 is put through a pin hole 13 which is communicated with the base parts of the tail parts 9&#39; in a longitudinal direction. Then, the tail parts 9&#39; are rocked so as to be freely swingable in the right and left directions in accordance with its action in a state where the pin 14 is engaged with the bearing parts 15 of the body part mainbodies 6 and also the both body part mainbodies 6 are integrated with a bond through the frame body 7. The eye recessed parts 16 are formed in the head parts of the body part mainbodies 6.  The eye parts where the pupils are provided inside glass eyeballs so as to be freely rockable are engaged with the eye recessed parts 16 at each side of the both body part mainbodies 6 before integration and the pupiles of the eye parts are moved in accordance with the action of the accessory 5.
The pharmaceutical formulations of the invention for masking the odor from the sulfur-containing active agent comprise at least one sulfur-containing active agent, an effective amount of at least one flavoring agent. Any flavoring agent or combinations of flavoring agents may be used in the pharmaceutical formulation of the invention. The flavoring agent may be natural flavors, natural fruit flavors, artificial flavors, and mixtures thereof. The pharmaceutical formulation may contain an artificial sweetener, a natural sweetener or mixtures thereof. The pharmaceutical formulations are provided in liquid dosage form or a dry powder dosage form for reconstitution in water. Stabilizer added as one of expicients can extend the stability of the pharmaceutical formulation liquid dosage form for a period of at least 30 days when the formulation is stored below room temperature. The pharmaceutical formulations of the invention are palatable and particularly useful for the administration of sulfur-containing drugs to very small children that are in need of such medications. Methods of forming a liquid dosage form of pharmaceutical formulation by adding water to the dry powder form, methods to prepare an odor-masking pharmaceutical formulation and methods for treating lead poisoning or Wilson&#39;s disease using the odor-masking pharmaceutical formulation are also provided.
FIELD: dentistry.SUBSTANCE: group of inventions concerns a dental curable composition, a method for its preparation and dental filling material based on it. The method for preparing the composition includes mixing polymerizable monomer (A), spherical filler (B) with an average diameter of primary particles from 230 to 290 nm; spherical filler (C) with an average diameter of primary particles from 150 to 350 nm having an average diameter of primary particles different from the diameter of spherical filler (B), and polymerization initiator (D). Fillers (B) and (C) are spherical particles of composite oxide based on silicon dioxide-oxide of a titanium group element; wherein 90% or more of particles that make up each of filler (B) and filler (C) have a diameter in the range of ±5% of the average diameter of primary particles. Polymerizable monomer (A) includes a set (meth)acrylic compounds. The refractive index of monomer (A) at 25°C is from 1.38 to 1.55; of fillers (B) and (C) - from 1.45 to 1.58 at 25°C. Monomer (A) and fillers (B) and (C) satisfy following conditions: nP&lt;nFBand nP&lt;nFC, where nP is the refractive index of polymer obtained by polymerization of monomer (A) measured at 25°C; nFBis the refractive index of filler (B) at 25°C; nFCis the refractive index of filler (C) at 25°C. At the same time, the difference between nFB and nFC indicators and nP indicator is from 0.001 to 0.015. Dental filling material consists of the dental curable composition of the above-mentioned content.EFFECT: composition can have a well-regulated shade of color without the use of dye, pigment, etc. and provides the convenience of application and aesthetics of dental filling material formed from it, the use of which provides filling, as a result of which the appearance of the formed cured product coincides with the appearance of natural teeth.10 cl, 4 tbl, 9 ex
The invention discloses a glycopeptide with immunoregulatory activity and application thereof. The glycopeptides are derived from chicken egg transferrin and include 14N-linked structures. The peptide segment part of the glycopeptide comprises TAGWVIPMGLIHNR and FGVNSCEK, the glycosylation site comprises 492 and 637, and the sugar chain contains N-acetylglucosamine, mannose and galactose. The glycosylation site of the glycopeptide peptide TAGWVIPMGLIHNR is 492, 12N-linked sugar chains, and the glycosylation site of the peptide FGVNGSEK is 637, 2N-linked sugar chains. The glycopeptide with immunoregulation provided by the invention can promote mouse macrophage RAW264.7 to secrete TNF-alpha. Transcriptome sequencing and proteomics and phosphorylation modification group analysis show that differential expressed genes, proteins, phosphorylated proteins of glycopeptides and panel cells are mainly focused on classical immune signaling pathways such as &#34;TNF signaling pathway&#34;, &#34;NF-kappa B signaling pathway&#34;, etc. The glycopeptide has high biocompatibility, tolerance and strong safety, and can be used as a promising candidate adjuvant.
PURPOSE: To produce a new high-purity crystal of 7-ethyltriptophol useful as an intermediate for etodolac as an anti-inflammatory agent by simple operations in high efficiency. CONSTITUTION: A crystal of 7-ethyltriptophol. The crystal preferably has a melting point of 46.5-51 deg.C, powder X-ray diffraction peaks at 12.9 deg., 17.2 deg., 24 deg. and 5.8 deg. (2θ) and/or peaks of an infrared absorption spectrum at wave lines of 1436, 1049 and 748 (cm&lt;-1&gt; ). The crystal is obtained from an oily substance of a crude 7-ethyltriptophol by dissolving it in an aprotic organic solvent such as benzene, treating the solution with an aqueous acidic solution (e.g. an aqueous hydrochloric solution) or a cation exchange resin and subsequently separating crystals from the obtained organic layer. Further, the concentration of the aqueous acidic solution is preferably 1-20%.  Furthermore, the aqueous acidic solution-treatment is preferably carried out at 0-50 deg.C by mixing the aqueous acidic solution into the solution prepared by dissolving the oily substance into an organic solvent.
PURPOSE:To obtain a dental material having low odor, low irritation and low water-absorption of polymer and giving a proper glutinous period when mixed with a powdery polymer by compounding a specific methacrylic acid ester compound. CONSTITUTION:The dental material is produced by compounding a methacrylic acid ester compound of formula I (m is 0 or integer of &gt;=1; n is integer of &gt;=1; m+n is integer of &gt;=2; R is H or methyl) (e.g. the compound of formula II or formula III). The compound of formula 1 is preferably further compounded with a polyfunctional methacrylate copolymerizable with the compound of formula I (e.g. ethylene glycol dimethacrylate or 1,6-hexanediol dimethacrylate). The material does not cause discomfortable feeling such as malodor and irritation of mucous membrane, etc. It has excellent durability of the dimension, strength, color, etc., in the palate as a cured material and is usable for a long period.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition for preventing onset of psychiatric disorder, and to provide a method for evaluating the possibility of the onset of the psychiatric disorder.  &lt;P&gt;SOLUTION: The composition contains an unsaturated fatty acid or an oil and fat containing at least one unsaturated fatty acid as a constituent fatty acid. The composition is regulated so as to be fed to the body at an immature stage of the brain tissue. The possibility of the onset of the psychiatric disorder by individual is evaluated based on a bonding strength by amplifying Fabp7 gene by using a genome DNA isolated from the individual as a template, and measuring the bonding strength between the polypeptide encoded by the Fabp7 gene and the unsaturated fatty acid. In another embodiment, the possibility of the onset of the psychiatric disorder by the individual is evaluated based on a base sequence by determining the base sequence of the Fabp7 gene on the genome DNA isolated from the individual.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
Embodiments of this invention include systems and methods for developing individualized dietary and health improvement plans based on an individual&#39;s intestinal microbiome and digestive activity. More particularly, the invention is related to a system providing a hydrogen and/or methane sensor device and a wireless platform in communication with the sensor device to periodically analyze the individual&#39;s metabolic activity in correlation with their gut microbiome and a personal database to provide personalized feedback to the individual of treatment plans and general techniques that can be used to improve the individual&#39;s general health and well being. The systems and methods further include a system for analyzing the hydrogen and/or methane levels in the individual&#39;s exhalations or flatulence in light of the individual&#39;s intestinal microbiome. This analysis uses bioinformatics to relate alterations in hydrogen and/or methane levels to the individual&#39;s intestinal microbiome and personal diet and tolerances/intolerances to identify and communicate real time dietary suggestions and general dietary and health treatment plans. The relationship of the bioinformatics and alterations in hydrogen and/or methane levels is also used to infer drug effectiveness. Such general dietary guidance, health treatment plans, and drug effectiveness contribute to an overall improvement in a person&#39;s general health and well being.
PROBLEM TO BE SOLVED: To provide a method for producing a low-molecular weight chitosan by which the low-molecular weight chitosan can inexpensively and stably be produced in large amounts and utilized for various fields and to provide a high-purity low-molecular weight chitosan suitable for utilization in the cutting-edge realm such as pharmaceuticals. SOLUTION: This method for producing the low-molecular weight chitosan comprises carrying out acid hydrolysis reaction of chitosan by using hydrochloric acid as a catalyst. The low-molecular weight chitosan having 10,000 to 20,000 weight-average molecular weight is preferably produced by the method. In the production method, acid hydrolysis reaction is carried out, preferably in &gt;=3% hydrochloric acid concentration and a weight of &gt;=5 times based on chitosan at &gt;=40 deg.C decomposition temperature of chitosan, more preferably in 5-8% hydrochloric acid concentration and a weight of 8-16 times based on chitosan at 70-90 deg.C decomposition temperature. In the production method, membrane-separation is carried out after acid hydrolysis reaction.  The low-molecular weight chitosan is preferably composed of the low-molecular weight chitosan having 10,000 to 20,000 weight-average molecular weight and a high-purity low-molecular weight chitosan having nearly 10,000 weight average molecular weight. A composition comprising the low molecular weight chitosan, preferably food, cosmetic or medicine is also provided.
A method for automatically assessing information processing speed in a test subject is disclosed. In the inventive method, a first qualimetric activity parameter for sensorial transmission, cognition and motoric output activity is determined and a second qualimetric activity parameter for sensorial transmission and motoric output activity is determined. A third qualimetric activity parameter for cognition is determined by comparing the first and the second qualimetric activity parameters to each other, and the information processing speed in the test subject is assessed based on the first, second and third qualimetric activity parameters. The information processing speed can be determined by comparing the determined qualimetric activity parameters to a reference and the subject&#39;s cognitive impairment can then be determined from the processing speed. The inventive method can be computer implemented. A mobile device or system for carrying out the disclosed methods is also disclosed.
PROBLEM TO BE SOLVED: To obtain a reactive tricalcium phosphate composition stable at room temperatures and giving α-tricalcium phosphate products in a pure phase by including a physiologically acceptable lubricant and a calcium phosphate cement composition comprising reactive α-tricalcium phosphate, a calcium source and a partially neutralized phosphoric acid source. SOLUTION: Reactive α-tricalcium phosphate is produced by reacting a stoichiometric mixture of CaHPO4 and CaCO3 with each other in an aqueous reaction solvent at a pressure of 0.35-2.1 kg/cm&lt;2&gt; , heating the obtained product having a Ca : phosphate group ratio of 1.5:1 at 1200-1700 deg.C for 1-8 hr and subsequently quenching the product. &gt;=20 wt.% of the obtained reactive α-tricalcium phosphate is compounded with 0.1-10 wt.% of at least one kind of an additional calcium source (e.g. calcium hydroxide) and 1.0-40 wt.% of a partially neutralized phosphoric acid source to obtain a calcium phosphate cement composition. The composition is compounded with a physiologically acceptable lubricant (e.g. water) to provide the objective reactive tricalcium phosphate composition.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes novel 2,3-trans-disubstituted tropan derivative of the general formula (I)   or   or their any mixture, or their pharmaceutically acceptable salt where: R means hydrogen atom, methyl, ethyl or propyl; R 3  means -CH 2 -X-R; where X means O or S and R&#39; means methyl, ethyl, propyl or cyclopropylmethyl; R 4  means phenyl that can be substituted with one or more substituents taken among the group consisting of halogen atom, CF 3  and CN. New tropan derivatives are strong inhibitors of reuptake of neuromediating monoamines, i. e. dopamine, serotonin and norepinephrine. New tropan derivatives can be used for treatment of patients with disorders or diseases that can be treated by inhibition of reuptake of neuromediating monoamines, for example, Parkinson&#39;s disease, depression, obsessive-compulsive disorders, panic states, dementia, memory disorder, hyperactivity with attention deficiency, obesity, fear state, appetite disorder, toxicomania and cocaine addiction. Invention describes also method of synthesis of compounds of the formula (I) and pharmaceutical composition based on thereof. EFFECT: new compound, improved method of synthesis, valuable pharmacological properties. 11 cl, 2 tbl, 16 ex
PURPOSE:To obtain the subject compound which is a stereoisomer derivative of epibatidine extracted from skin of a toxic frog and having nonopioid analgesic action in high yield by subjecting a compound having a specific structure to deprotection. CONSTITUTION:An endo-halopyridyl-N-protected azabicycloheptane of formula I (R&lt;1&gt; is formyl, allyl, etc.; R&lt;2&gt; is halogen) {e.g. endo-2-(6&#39;-chloro-3&#39;-pyridyl)-7- ethoxycarbonylazabicyc lo-[2.2.1]heptane} is deprotected to provide the objective compound of formula II (X is anion). The protection is preferably carried out by catalytic reduction or acid hydrolysis using hydrochloric acid, etc. Furthermore, the compound of formula I is preferably obtained by successively carrying out reduction, hydrolysis, introduction of N-protecting group, formation of sulfonic acid ester, deprotection and base treatment using a compound of formula III as a starting raw material, introducing a N-protecting group to the produced compound of formula IV, treating the resultant compound with a peracid, etc., and successively reacting the resultant compound of formula V with a halogenating agent.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a useful means for the local treatment of prostatic cancer, excellent in safety, and also a useful means for the local treatment even in cancers resembling the prostatic cancer.  &lt;P&gt;SOLUTION: This local cancer-treating agent contains a polyethylene glycol as an active ingredient. The polyethylene glycol has 1,000 to 10,000 range number-average molecular weight. The contained concentration of the polyethylene glycol is 0.1 to 50 mass% range. The cancer is selected from prostatic cancer, hepatic cancer, bladder cancer, breast cancer and colon cancer.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
Apparatus for concealing vitiligo and unwanted tan lines is provided. The apparatus includes a cosmetic applicator. The cosmetic applicator includes a spring head. The spring head may be covered by a covering. Depression of the spring head may saturate the covering with a solution. The solution may include a bronzer and dihydroxyacetone (&#34;DHA&#34;).
A nasal drug delivery device for delivering a plume derived from a propellant and a drug compound. The drug compound is in an intranasal dosage form in the form of powder, suspension, dispersion, or liquid. The propelled intranasal dosage form is deposited within the upper nasal cavity such as the olfactory region. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing channel where the intranasal dosage form is aerosolized. The aerosolized intranasal dosage form passes through a nozzle thus delivering a plume to the user&#39;s upper nasal cavity.
PURPOSE: To obtain a viable bacterium preparation containing a viable bacteri um and chlorella powder as an excipient, useful for medicines, foods, etc., and capable of enhancing the survival rate of bacterial cells after prepared. CONSTITUTION: The viable bacterium preparation contains a viable bacterium, preferably lactobacillus, as a main ingredient and 60-90wt.% of chlorella powder as an excipient. The chlorella powder has following properties; a particle degree distribution: particle sizes of &lt;=149μm: 80-98%, particle sizes of 150-250μm: 2-20%; a bulk density of 0.37±0.05; a tap density: 0.46±0.05g/cm&lt;3&gt; ; and an angle of repose: 42±5 degree. The addition of a conventional binder such as crystalline cellulose, calcium carboxymethylcellulose or α-starch to the chlorella in an amount of 3-20wt.% gives tablets high in hardness without killing the viable lactobacillus. If necessary, a lubricant, a perfume, a pigment, a pharmacodynamic ingredient, etc., may be added to prepare a formulation. The tabletting enables to prevent abrasion and defects generated on storage or carriage.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a cleansing composition having good cosmetic properties and rapidly rinsed off.  &lt;P&gt;SOLUTION: The cleansing composition for topical application comprises a surfactant system containing (1) one kind or a plurality of kinds of anionic surfactants selected from alkyl glycol carboxylic acids and salts thereof and (2) one kind or a plurality of kinds of alkylbetaines in a physiologically acceptable aqueous medium in which the total amount of the alkyl glycol carboxylic acids and salts thereof and of the alkylbetaines is at least 50% of the total weight of the surfactant system. Furthermore, the use of the composition, in particular in the cosmetics or dermatological fields as products for cleansing or for removing makeup from the skin, the scalp and/or the skin is provided. The anionic surfactant may in particular be sodium lauryl glycol carboxylate [Beaulight Shaa (R)] or its acid form. The composition has the good cosmetic properties and the foam obtained is fine and rinses off well.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain the subject medicine containing a specific azole derivative as an active ingredient, capable of exhibiting a strong active oxygen release- suppressing action, and useful for the disorders of tissues after ischemic reperfusions. SOLUTION: This medicine contains an azole derivative of formula I (R&lt;1&gt; , R&lt;3&gt; are each phenyl which may have one to five substituents, such as an alkoxy, a lower alkyl or hydroxyl group, on the phenyl ring, a 5-15 membered mono, di or tricyclic heterocyclic residue which has one or two of N atoms, O atoms or S atoms, etc.; X is S atom, O atom, etc.) or its salt as an active ingredient. The compound of formula I includes 2-(3,4-diethoxyphenyl)-4-(3-carboxy-5- methoxyphenyl)thiazole. The compound of formula I is obtained by reacting a compound of formula II (Y is a halogen) and a compound of formula III in a proper solvent.